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Abstract
Aim of the study: Few population-based studies have been conducted to report the prevalence of non-alcoholic 
fatty liver disease (NAFLD) and determine its risk factors in Iran, particularly in Shahrekord, southwest Iran. 
The main aim of this population-based, case-control study was to determine the prevalence of NAFLD and its 
potential risk factors in an Iranian population-based cohort study in Shahrekord, Iran.
Material and methods: We compared 1153 cases with NAFLD at 35 to 70 years to 1153 frequency-matched 
NAFLD-free controls from a population-based Shahrekord cohort study. Data collection and assessed risk factors 
(demographics, anthropometrics, clinical and biochemical factors, and laboratory tests) were performed based on 
the Shahrekord cohort study protocol. Chi-square test, stepwise selection with backward likelihood ratio, logistic 
regression and log-binomial regression model with 95% confidence interval were performed to determine risk 
factors with significant effects on NAFLD.
Results: In this study, the mean (± standard deviation) age of the participants was 50.23 (±8.70) years. The 
prevalence of NAFLD and metabolic syndrome with 95% confidence interval were 16.47% (15.61-17.36%) 
and 32.74% (30.83-34.70%), respectively. There was a significant difference in the frequency of waist circum-
stance, triglycerides, body mass index, blood pressure, and alanine aminotransferase between cases and controls 
(p < 0.001). According to log-binomial model results, socioeconomic status, hypertension, diabetes, and physical 
activity were significantly associated with NAFLD.
Conclusions: Our findings have important clinical and public health implications in southwest Iran for moni-
toring the prevalence of NAFLD and important risk factors to manage, screen, prevent, and reduce NAFLD and 
related factors.
Key words: risk factor, prevalence, non-alcoholic fatty liver disease, Shahrekord cohort study, log-binomial 
regression model.
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guidance from the American Association for the Study 
of Liver Disease, NAFLD is defined as the presence of 
hepatic steatosis (HS) in absence of secondary causes 
of hepatic fat accumulation including significant alco-
hol intake, use of a steatogenic medication for a long 
time, or monogenic hereditary disorders [1, 2]. With 
Introduction
Non-alcoholic fatty liver disease (NAFLD) is one 
of the significant types of liver diseases in patients 
with metabolic comorbidities, such as obesity, diabetes 
mellitus, and dyslipidemia [1]. According to practice 
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regards to etiological criteria, NAFLD is classified as 
non-alcoholic fatty liver (NAFL) and non-alcoholic 
steatohepatitis (NASH) with or without cirrhosis [3]. 
NAFL is defined as the presence of over 5% of HS, and 
lack of hepatocellular injury in the form of hepatocyte 
ballooning [1].
Due to the increasing prevalence of obesity and 
changes in lifestyle, for example, variation in dietary 
habits along with decreased physical activity in the 
eastern countries, the prevalence of NAFLD dramati-
cally increased in the previous decade [4, 5]. At present, 
various studies and guidelines demonstrate that there 
is a close association between NAFLD and metabolic 
risk factors, particularly dyslipidemia, type 2 diabetes 
mellitus (T2DM) and visceral obesity and other com-
ponents of metabolic syndrome (METS) [4]. While 
all metabolic disorders are known as risk factors for 
NAFLD, the high prevalence of NAFLD is predictable 
[5]. However, according to the diagnostic tools used, 
the reported prevalence of NAFLD is 10-35% in the 
general population [4]. There is important variation in 
the prevalence and risk factors for NAFLD in the Ira-
nian population among different geographical regions 
[4]. According to several epidemiological studies in 
Iran, T2DM is highly associated with NAFLD. More-
over, NAFLD and NASH prevalence in Iranian pa-
tients with T2DM is 55.8% [6], and has changed from 
2.9% to 7.1% in the general population [7-9]. Another 
important risk factor of NAFLD, which is defined by 
income and education, was socioeconomic status [10]. 
Interestingly, medical researchers have shown that fat-
ty liver is also associated with hypertension [11]. In 
particular, NAFLD was found to occur more frequent-
ly in hypertensive patients [11]. 
Because few studies have been conducted on the 
prevalence of NAFLD in southwest Iran, particularly 
Shahrekord (height above mean sea level is around 
2153 m and therefore this city is known as Iran’s roof), 
monitoring the prevalence of NAFLD and important 
risk factors is essential for management, screening, pre-
vention, and reduction of NAFLD and related factors. 
Several studies have used regression analysis to identify 
and determine risk factors for NAFLD as a  dichoto-
mous outcome [5]. Due to increasing use of multiple 
logistic regression for modeling dichotomous outcomes 
in medical research, the need for efficient models with 
greater accuracy has been intensified in certain situa-
tions [12]. In epidemiological studies, the dichotomous 
outcome is frequently analyzed by logistic regression. 
Since the prevalence ratio is overestimated by the odds 
ratio in logistic regression, a  log-binomial regression 
model can provide correct estimates and serve as a bet-
ter alternative than logistic regression [13]. 
The main aim of this population-based, case- 
control study was to determine the prevalence of 
NAFLD and its potential risk factors in an Iranian 
population-based cohort study in Shahrekord, south-
west Iran.
Material and methods
Study type
This population-based, case-control study was con-
ducted within the Shahrekord Cohort Study (SCS) on 
subjects aged 35-70 years. This study was designed to 
serve as one of the centers of the Prospective Epidemi-
ological Research Studies in Iran (PERSIAN) Cohort 
and is being conducted in Chaharmahal and Bakhtiari 
province, southwest of Iran. First, NAFLD prevalence 
in the whole cohort was estimated. Then, the individu-
als with NAFLD (n = 1153) were considered cases. 1153 
controls were selected from sex-frequency matched 
subjects without NAFLD in the SCS. The sample size 
of the original cohort was 10078 people, with a 20-year 
follow-up, who were selected by a multistage, stratified 
cluster random sampling. The study protocol of the 
SCS was reviewed and approved by the Ethics Com-
mittee of Shahrekord University of Medical Sciences 
(IR.SKUMS.REC 1394.286). Details of the SCS proto-
col have been published in other studies [14, 15]. 
Case and control population, the inclusion  
and exclusion criteria, risk factors
Patients with chronic liver disease, patients with 
a history of significant excessive alcohol consumption 
(more than 20  g daily for women and 30 g daily for 
men) who were regarded as suffering from alcohol-
ic liver disease [16], patients with viral and autoim-
mune hepatitis, and patients with cognitive disorders 
and women who were pregnant were excluded from 
study. To participate in the SCS, people were invited by 
a dated letter of invitation given to them in person and 
then, before the day of their referral, they were recalled 
by telephone [14]. 
Data on demographics, socioeconomic status and 
anthropometric characteristics, occupational history and 
exposures, lifestyle and physical activity were collected 
using standard questionnaires. Physical examinations 
and medical questionnaire were also used to investigate 
history of chronic diseases, recommended pharmaco-
logical therapies for NAFLD/NASH based on guidelines 
(metformin hydrochloride, pioglitazone, vitamin E, 
ursodeoxycholic acid) [17], family medical history and 
individual habits (smoking and alcohol use). A  stan-
dard barometer was used to measure blood pressure in 
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the right and left arms twice (with a 15-min interval); 
finally, the average of the two measures of the left and 
right arm was considered the blood pressure. Biochem-
ical tests including fasting blood sugar, serum cholester-
ol, triglycerides, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL) and cholesterol 
were measured by using blood samples of participants 
with a Pars Azmoon kit [14]. NAFLD was diagnosed by 
a hepatologist on the basis of ultrasonography and medi-
cal records. The definition of National Cholesterol Educa-
tion Program Adult Treatment Panel III criteria (ATPIII) 
was used for diagnosis of METS [18]. The presence of 
any 3 of the following 5 criteria was required for the diag-
nosis: fasting serum glucose ≥ 100 mg/dl, waist circum-
ferences (WC) (> 102 cm in men; > 88 cm in women), 
triglyceride (TG) ≥ 150 mg/dl, HDL (< 40 mg/dl in men; 
< 50 mg/dl in women), blood pressure (BP) ≥ 140 (SBP) 
or ≥ 90 (DBP) mmHg.
Additionally, socioeconomic status was determined 
by measuring a combination of education level and 
a checklist of income and occupation. Principle com-
ponent factor analysis (KMO = 0.719, Bartlett’s sphe-
ricity test and p-value < 0.001) was applied to deter-
mine the socioeconomic status. The socioeconomic 
status factor was converted to an ordinal variable and 
was labeled as low, medium, and high level.
Statistical analysis
Demographics and historical exposure were cate-
gorized according to the SCS protocol and METS defi-
nition. Descriptive characteristics of the participant 
were expressed as the mean ± standard deviation (SD) 
and frequency (percentage) for continuous and cate-
gorical variables, respectively.
Two separate frequency tables described all vari-
ables in the total population including prevalence of 
NAFLD in each category of variables for METS as well 
as demographic and exposure variables, respectively. 
The frequency of each pharmacological therapy which 
was taken by patients with NAFLD was reported. 
The χ2 test was applied to compare the frequency of 
these variables between the patients who had NAFLD 
and controls who did not have NAFLD. Stepwise se-
lection with backward likelihood ratio was used to in-
vestigate the best subset of variables in which the best 
fit in the logistic regression model could be achieved. 
Variance inflation factor (VIF) was used to investigate 
the presence of multicollinearity between the covari-
ates. The best subset of variables which were drawn 
from the logistic regression model was assessed in the 
log-binomial regression fitting. Finally, a log-binomial 
regression model was used to determine risk factors 
that had significant effects on NAFLD. The results were 
presented as risk ratios (RRs) from the log-binomial 
regression model. The RR in the log-binomial mod-
el demonstrates in which groups of variables the risk 
of interested outcome is greater than that in the oth-
er groups [19]. If the value of RR in the log-binomial 
model is greater than one, the risk of the outcome in 
the baseline group is more than that in the other group 
and vice versa [20]. The 95% confidence intervals 
(95% CI) were demonstrated for the estimated effect 
sizes. Stata software, version 13, was used to perform 
the models and a  p-value < 0.05 was considered the 
level of statistical significance.
Results
The mean (± standard deviation) age was 50.23 
(±8.70) years. The prevalence (95% CI) of NAFLD 
and METS in this study was 16.47% (15.61-17.36%) 
and 32.74% (30.83-34.70%), respectively. Mean (and 
standard deviation) body mass index (BMI) in case 
and control groups was 30.02 (4.48) and 27.88 (4.39), 
respectively. 
The participants’ characteristics and χ2 test results 
are shown in Table 1 and Table 2. According to the re-
sults of Table 1 and Table 2, the difference in preva-
lence between the patients who had NAFLD and the 
controls who did not have NAFLD was significant 
with respect to diabetes (p < 0.001), hypertension 
(p < 0.001), physical activity (p < 0.001), and METS 
(p < 0.001). Furthermore, the results of Table 2 show 
that there is a  significant difference between the fre-
quency of WC, TG, BMI, BP and ALT (all p-values 
< 0.001) between cases and controls. Three compo-
nents of metabolic syndrome which were not signifi-
cantly different between the two groups were fasting 
serum glucose, HDL and total cholesterol (Table 2). 
The stepwise selection indicated that socioeconomic 
status, hypertension, alcohol consumption, diabetes, 
physical activity, and METS had the best fit in the lo-
gistic model while the presence of multicollinearity 
between covariates was investigated based on the VIF 
values. Therefore, all these variables were used in the 
log-binomial regression model.
The results of the log-binomial regression model are 
presented in Table 3. According to the estimations of 
the log-binomial model, socioeconomic status, hyper-
tension, diabetes and physical activity were significantly 
associated with NAFLD. Subjects who had a low/medi-
um level of socioeconomic status were less likely to have 
NAFLD than individuals who had a high socioeconomic 
level (low level: RR = 0.88, 95% CI: 0.80-0.96, p = 0.004; 
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Table 1. Frequency of demographic characteristics and potential risk factors of participants by NAFLD status along with chi-square test
Variable Total (%) NAFLD status P-value
Yes (%) No (%)
Age (years) 0.459
< 40 289 (12.5) 135 (46.7) 154 (53.3)
40-60 1631 (70.7) 820 (50.3) 811 (49.7)
≥ 60 386 (16.7) 198 (51.3) 188 (48.7)
Gender 0.994
Male 920 (39.9) 460 (50.0) 460 (50.0)
Female 1386 (60.1) 693 (50.0) 693 (50.0)
Education 0.419
≤ Diploma degree 1584 (68.7) 783 (49.4) 801 (50.6)
> Diploma degree 722 (31.3) 370 (51.2) 352 (48.8)
Marital status 0.115
Single 33 (1.4) 12 (36.4) 21 (63.6)
Married 2170 (94.1) 1096 (50.5) 1074 (49.5)
Widowed/Divorced 103 (4.5) 45 (43.7) 58 (56.3)
Ethnicity 0.072
Fars 1398 (60.6) 679 (48.6) 719 (51.4)
Tork 279 (12.1) 135 (48.4) 144 (51.6)
Lor 629 (27.3) 339 (53.9) 290 (50)
Job status 0.676
Unemployment 1248 (54.1) 629 (50.4) 619 (49.6)
Employment 1058 (45.9) 524 (49.5) 534 (50.5)
Socioeconomic status 0.112
Low level 710 (30.8) 337 (47.5) 373 (52.5)
Medium level 929 (40.3) 467 (49.7) 467 (50.3)
High level 667 (28.9) 313 (53.1) 313 (46.9)
Alcohol consumption 0.335
Yes 371 (16.1) 194 (52.3) 177 (47.7)
No 1935 (83.9) 959 (49.6) 976 (50.4)
Type 2 diabetes mellitus < 0.001
Yes 329 (16.1) 229 (69.6) 100 (30.4)
No 1977 (83.9) 924 (46.7) 1053 (53.3)
Hypertension (SBP ≥ 140 or DBP ≥ 90 mmHg) < 0.001
Yes 523 (22.7) 332 (63.5) 191 (36.5)
No 1783 (77.3) 821 (46.0) 962 (54.0)
Ischemic heart disease 0.133
Yes 154 (6.7) 86 (55.8) 68 (44.2)
No 2152 (93.3) 1067 (49.6) 1085 (50.4)
Smoking 0.853
Yes 301 (13.1) 152 (50.5) 149 (49.5)
No 2005 (86.9) 1001 (49.9) 1004 (50.1)
Physical activity < 0.001
Very low 223 (9.7) 135 (60.5) 88 (39.5)
Low 1125 (48.8) 590 (52.4) 535 (47.6)
Moderate 722 (31.3) 344 (47.6) 378 (52.4)
High 236 (10.2) 84 (35.6) 152 (64.4)
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Table 3. Estimation based on log-binomial regression model using best subset variables according to stepwise selection (backward LR)
Variable Risk ratio Standard error 95% confidence interval P-value
Lower Upper
Socioeconomic status
Medium level 0.80 0.04 0.72 0.88 < 0.001
Low level 0.88 0.04 0.80 0.96 0.004
Physical activity
Moderate 1.26 0.12 1.05 1.52 0.012
Low 1.38 0.12 1.16 1.65 < 0.001
Very low 1.46 0.15 1.20 1.78 < 0.001
Type 2 diabetes (yes) 1.34 0.06 1.22 1.47 < 0.001
Hypertension (yes) 1.19 0.06 1.08 1.31 < 0.001
Alcohol consumption (yes) 1.11 0.06 1.00 1.23 0.058
METS (yes) 1.08 0.05 0.98 1.19 0.102
Table 2. Prevalence of NAFLD in biochemical parameters, anthropometric indexes, and metabolic syndrome components according to NAFLD status along with 
the results of chi-square test
Variable n (%) NAFLD status P-value
Yes (%) No (%)
Waist circumference (cm) < 0.001
> 102 in males 221 (15.9) 147 (66.5) 74 (33.5)
> 88 in females 1173 (84.1) 590 (50.3) 583 (49.7)
Blood pressure (mmHg) < 0.001
SBP ≥ 140 354 (15.4) 184 (52) 170 (48)
DBP ≥ 90 507 (22) 273 (53.8) 234 (46.2)
Fasting serum glucose (mg/dl) ≥ 100 1080 (46.8) 524 (48.5) 556 (51.5) 0.182
Triglycerides (mg/dl) ≥ 150 1199 (52.0) 685 (57.1) 514 (42.9) < 0.001
HDL (mg/dl) 0.609
< 40 in males 168 (18.3) 87 (51.8) 81 (48.2)
< 50 in females 425 (30.7) 222 (52.2) 203 (47.8)
Serum cholesterol (mg/dl) > 200 927(40.2) 450(48.5) 477(5105) 0.251
ALT (U/l) ≥ 40 258 (11.2) 170 (65.9) 88 (34.1) < 0.001
AST (U/l) ≥ 40 54 (2.3) 33 (61.1) 21 (38.9) 0.098
BMI (kg/m2) < 0.001
< 25 (normal) 397 (17.2) 115 (29.0) 282 (71.0)
≥ 25 – < 30 (overweight) 1077 (46.7) 529 (41.9) 548 (50.9)
≥ 30 (obese) 832 (36.1) 509 (61.2) 323 (38.8)
Metabolic syndrome (ATPIII) < 0.001
Yes 775 (33.6) 431 (55.6) 344 (44.4)
No 1531 (66.4) 722 (47.2) 809 (52.8)
medium level: RR = 0.80, 95% CI: 0.72-0.88, p < 0.001). 
In the current study people with T2DM had 1.34 times 
higher risk of having NAFLD than people who did not 
have T2DM (RR = 1.34, 95% CI: 1.22-1.47, p < 0.001). 
The risk of having NAFLD in participants with hyperten-
sion was significantly higher than in those without hy-
pertension (RR = 1.19, 95% CI: 1.08-1.31, p < 0.001). In 
participants who had very low, low, and moderate physi-
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cal activity the risk of having NAFLD was 1.46, 1.38, and 
1.26 times higher than in those who had a high level of 
physical activity (very low level: RR = 1.46, 95% CI: 1.20-
1.78, p < 0.001; low level: RR = 1.38, 95% CI: 1.16-1.65, 
p < 0.001; moderate level: RR = 1.26, 95% CI: 1.05-1.52, 
p = 0.012). Alcohol consumption was not identified as 
a significant factor in the log-binomial model. However, 
the risk of having NAFLD in patient who used alcohol was 
1.11 times higher than in those who did not consume 
alcohol (RR = 1.11, 95% CI: 1.00-1.23, p = 0.058).
A list of recommended pharmacological therapies 
for NAFLD based on guidelines was provided. Our 
results indicated that the frequency and the percent-
age of using metformin hydrochloride among NAFLD 
patients are higher than for other drugs [metformin 
hydrochloride: 248 (6.42); pioglitazone: 4 (0.103); vita-
min E: 26 (0.67); ursodeoxycholic acid: 5 (0.12)]. 
Discussion
In the current study, we investigated the prevalence 
of NAFLD and its associated risk factors in an Iranian 
population at enrolment phases of the SCS. Our results 
showed that the prevalence of NAFLD was 16.47%, 
and after adjusting for confounding variables type 2 
diabetes mellitus, hypertension, socioeconomic status 
and physical activity were significantly associated with 
NAFLD. To the best of our knowledge, this is the first 
study to report the prevalence of NAFLD and establish 
its risk factors in a relatively large number of subjects 
in southwest Iran.
According to recent epidemiological studies world-
wide, the global prevalence of NAFLD has been re-
ported at 24% [21]. Although NAFLD is regarded as 
a  prevalent disease of high burden in all countries, 
the highest rate belongs to the Middle East (32%) and 
South America (31%) [21]. As expected, there is wide 
variation in prevalence of NAFLD in the Asia-Pacific 
region associated with disparities in socioeconomic 
level as well as lifestyle differences among countries of 
the region [22]. Consistent with these findings, there 
was an obvious difference in prevalence of NAFLD be-
tween the current study and the other ones conduct-
ed in the Asia-Pacific region. This notable variation 
may be attributed to the type of diagnostic tools used 
in our study and also the absence of misclassification 
in diagnosis of NAFLD. Since in our study the criteria 
for NAFLD diagnosis were both the confirmation of 
NAFLD by a hepatologist and liver sonography, indi-
viduals who did not fulfill these criteria were not in-
cluded in this study. Furthermore, because of the be-
nign and reversible condition of NAFLD and absence 
of obvious and specific clinical symptoms, diagnosis of 
NAFLD can be a complex process. Therefore, NAFLD 
may also be observed in non-obese individuals, pa-
tients without clinical manifestations of METS, and all 
people who do not refer for diagnostic tests. These rea-
sons may lead to a wide variation in the prevalence of 
NAFLD (10-35%) in population-based studies [4, 23].
In our study, a borderline significant association be-
tween alcohol consumption and NAFLD was found in 
the log-binomial model. Various studies have demon-
strated that low-moderate alcohol consumption might 
decrease the likelihood of developing NAFLD [24] and 
excessive use of alcohol is the cause of most cases of 
fatty liver disease, but recently, diverse factors such 
as insulin resistance, oxidative stress, mitochondrial 
dysfunction, immune deregulation, and adipokines 
have become more important in the pathogenesis of 
NAFLD [25].
Several studies especially in Iran have shown that 
NAFLD is associated with METS [5]. However, in the 
current study, the effect size of METS was not signifi-
cantly associated with NAFLD. Explicit epidemiologi-
cal evidence has shown that all NAFLD patients may 
not be classified as cases of METS, and also all patients 
with METS may not develop NAFLD. Therefore, there 
are some other risk factors that are not related to METS 
yet cause NAFLD in patients [26]. 
Studies recently conducted in the US have demon-
strated that T2DM and NAFLD have common risk 
factors and there is a strong association between them 
[27]. T2DM was also found to be one of the risk fac-
tors for NAFLD in the current study. Although T2DM 
appears to intensify the progress of NAFLD, the liver 
disease makes diabetes management more problem-
atic and the mechanism of this association remains 
unknown. Diabetes may encourage the development 
of NASH, i.e., a more severe form of the disease, and 
increase the risk of cirrhosis and hepatocellular carci-
noma [8].
The association between NAFLD and hypertension 
has been a controversial issue in several studies. Many 
clinical researchers have evaluated the relationship be-
tween these two diseases with or without other accom-
panying factors [28]. Our findings are in accordance 
with recent studies, and hypertension is a risk factor for 
NAFLD. A probable mechanism of this association is 
that hypertension has a significant effect in the patho-
genesis of METS, which in turn can influence the pro-
gression of NAFLD in patients with hypertension [28].
Interestingly, physical activity has been considered 
a vital factor for managing NAFLD in several studies. 
These studies have discussed the beneficial effect of 
increasing physical activity on reducing the progress 
of NAFLD, and also they have argued that promoting 
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and maintaining physical activity provide health ben-
efits for NAFLD patients [29]. In our study, a  strong 
association was found between NAFLD and very low, 
low and moderate levels of physical activity.
In the current study, although socioeconomic sta-
tus was one of the most significant contributing factors 
associated with NAFLD, patients in low and moderate 
socioeconomic classes had lower risk of developing 
NAFLD. These findings have also been obtained in 
several studies such as those of Santos et al. and Ma-
nuck et al. [30, 31]. 
Our study had some limitation regarding NAFLD 
diagnosis. Although ultrasonography and medical re-
cords were used for diagnosis of NAFLD in this study, 
liver biopsy could have also been a  gold standard 
method for NAFLD diagnosis. However, because of 
research ethics, we did not use it. A large sample size 
which can be representative of the study population, 
high-quality data, proper statistical method and also 
controlling for confounding variables are the most im-
portant advantages of this study.
Conclusions
Our findings have important clinical and public 
health implications in southwest Iran for monitoring 
the prevalence of NAFLD. The current study, as a clini-
cal report, established 4 risk factors (hypertension, type 
2 diabetes mellitus, physical activity, and socioeconom-
ic status) for NAFLD. This study suggests that these sig-
nificant risk factors should be taken into account in the 
screening, prevention, and reduction of NAFLD.
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